The Annual General Meeting of ChronTech Pharma AB

The Annual General Meeting of ChronTech Pharma AB was held in Stockholm on April
16th, 2012.

Annual Report and discharge from liability

The Company's
Income Statement and Balance Sheet were adopted and the Board of Directors and
the Chief Executive Officer were discharged from liability for the financial
year 2011.

Election of Board of Directors and Chairman of the Board and
compensation to the Board

Thomas Lynch, Anders Vahlne, Matti Sällberg,
William W Hall, John Climax, Prem Lachman and Simon Kukes were re-elected as
members of the Board.

Thomas Lynch was re-elected as Chairman of the
Board.

The Meeting resolved that directors' fees of in total SEK 200,000
shall be payable to William W Hall.

Authorisation to issue new shares,
warrants and convertible debentures

The Meeting resolved to authorize the
Board to resolve, at one or more occasions until the next Annual General
Meeting, and with or without the shareholders pre-emption rights, to issue new
shares, share warrants and/or convertible debentures. Payment shall be made in
cash and/or in kind or by set-off or otherwise with conditions. The purpose of
the authorization is to enable the Company to raise working capital. The reason
for disapplaying the shareholders’ pre-emption rights is to facilitate the
procurement of capital. If new issue of shares is paid in cash without the
shareholders pre-emption rights the issuing conditions must be market
oriented.

For more information, please contact:

Anders Vahlne, CEO and
Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28,
E
-mail: anders.vahlne@ki.se

About ChronTech

ChronTech develops the
therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic
hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with
jaundice causing viruses which can lead to liver cirrhosis and liver cancer.
ChronTech has also developed and further develops a patent pending new type of
injection needle for a more effective uptake of DNA vaccines. ChronTech also
have part ownership in the wound healing therapy ChronSeal®, and in the new
platform technology RAS®. The ChronTech share is admitted to trade on First
North. Remium Nordic AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se

In the event of any discrepancy
between the Swedish and English versions of this press release, the Swedish
version will take precedence.